Insmed has announced the discontinuation of its development program for Brinsupri, a first-in-class DPPI inhibitor, after a phase 2 trial failed to demonstrate efficacy in treating chronic rhinosinusitis without nasal polyps (CRSsNP). This setback marks a significant blow for the company, which had high expectations for Brinsupri following its recent approval in other indications.
The failure of this trial not only impacts Insmed’s pipeline but also raises questions about the viability of DPPI inhibitors in treating CRSsNP. The discontinuation of Brinsupri may lead to a reevaluation of the company’s strategic focus and resource allocation, particularly as it seeks to maintain investor confidence amidst declining share prices. The broader implications for the industry could involve increased scrutiny on clinical trial designs and the need for robust data supporting the efficacy of novel therapies in niche indications.
Get started today with Solo access →
